Please login to the form below

I have forgotten my password

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

GSK sells eczema and psoriasis drug to Dermavant for £250m

s Xeljanz (tofacitinib), Incyte/Eli Lilly’s Olumiant (baricitinib) and AbbVie’s upadacitinib.

Latest news

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

They think the drug could overtake Pfizer’s Xeljanz (tofacitinib), the first JAK inhibitor to reach the market for RA with sales of $1.35bn last year, but say this could ... Meanwhile, following the same path as Xeljanz, upadacitinib is also being
Pfizer’s Xeljanz picks up a third indication in IBD

Pfizer’ s Xeljanz picks up a third indication in IBD. The JAK inhibitor can now treat US patients with ulcerative colitis. ... With the FDA approval of Xeljanz, adults living with moderately to severely active UC now have an oral option that may help
Pfizer’s Xeljanz picks up a third indication in the US

The JAK inhibitor can now treat patients with ulcerative colitis. The US Food and Drug Administration (FDA) has given its seal of approval to Pfizer’s Xeljanz (tofacitinib), a JAK inhibitor ... With the FDA approval of Xeljanz, adults living with
Pfizer’s flat sales focus investor attention on M&A

Once again, cancer drug Ibrance (palbociclib), anticoagulant Eliquis (apixaban) and Xeljanz (tofacitinib) for arthritis and other immunological indications led the charge, backed up by a solid advance for paediatric vaccine Prevnar
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy

More from news
Approximately 20 fully matching, plus 39 partially matching documents found.

Latest Intelligence

Pharma deals during September 2013

antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Brand leaders in RA will lose market share, predict rheumatologists

JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. ... The EMA’ s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in